Secondary outcomes
| Within-group | Between-group | ||||
|---|---|---|---|---|---|
| Variable | Baseline | 3 m | meanΔ 95% CI (ll to ul) | meanΔ 95% CI (ll to ul)* | p Value* |
| 6MWD (m) | |||||
| UCG | 450±106 | 449±118 | −0.81 (−7.7 to 6.1) | 13.4 (3.40 to 23.5) | 0.009 |
| IG | 444±106 | 457±108 | 12.7 (5.4 to 20.1) | ||
| QF (kg) | |||||
| UCG | 32.0±9.7 | 31.7±9.3 | −0.356 (−1.59 to 0.88) | 0.340 (−1.38 to 2.06) | 0.697 |
| IG | 31.7±11.0 | 31.8±10.3 | 0.102 (−1.35 to 1.55) | ||
| CAT (points) | |||||
| UCG | 13 (8–18) | 13 (9–20) | 1.09 (0.032 to 2.15) | −0.57 (−1.88 to 0.74) | 0.391 |
| IG | 13 (7–20) | 14 (9–19) | 0.62 (−0.346 to 1.59) | ||
| CCQmental state | |||||
| UCG | 1 (0–2) | 1 (0–2) | 0.198 (−0.116 to 0.51) | −0.133 (−0.326 to 0.061) | 0.178 |
| IG | 1 (0–2.5) | 1 (0–2.5) | −0.031 (−0.320 to 0.257) | ||
| CCQfunctional state | |||||
| UCG | 1.5 (0.75–2.5) | 1.75 (0.75–2.75) | 0.64 (0.060 to 1.23) | −0.203 (−0.382 to −0.024) | 0.026 |
| IG | 1.5 (1–2.75) | 1.5 (1–2.75) | −0.069 (−0.639 to 0.50) | ||
| CCQsymptoms | |||||
| UCG | 1.75 (1.5–2.75) | 2 (1.25–2.75) | 0.94 (0.281 to 1.59) | −0.085 (−0.263 to 0.094) | 0.352 |
| IG | 1.75 (1.25–2.5) | 1.75 (1.25–2.5) | 0.97 (0.378 to 1.56) | ||
Data are presented as mean±SD, median (Q1-Q3), within-group and between-group differences are presented as mean Δ 95% CI (ll to ul). Analyses are based on 299 (6MWD, 94% of completers), 243 (QF, 76% of completers), 317 (CAT, 100% of completers) and 316 (CCQ, 99% of completers) patients.
*Adjusted for baseline outcome.
6MWD, 6-min walk distance; CAT, COPD assessment test; CCQ, clinical COPD questionnaire; IG, intervention group; QF, quadriceps force; UCG, usual care group.